Latest filing published 14 Jun 2017 for IVERIC bio, Inc., €1,574.
Filing timeline
BuySaleInsider track record
No signal scores available.
David E. Redlick: trading record in brief
David E. Redlick discloses dealings in IVERIC bio, Inc. to SEC (Form 4). Between 18 May 2017 and 13 June 2017, the trades on record add up to 2 filings.
No open-market purchase appears, only 1 sale worth €1,574. Outside the open market, there are 1 option exercise.
The newest entry dates from 14 June 2017: an open-market sale of €1,574, in IVERIC bio, Inc. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to David E. Redlick
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 700 shares@ US$2.52100.0% of flowCommon StockSEC:0001104659-17-039277:0
- 1,750 sharesCommon StockSEC:0001104659-17-034325:0
2 of 2 declarations
